COMMD5 and renal carcinoma: Our studies also demonstrate that HCaRG overexpression inactivates the MAPK and PI3K/AKT signaling pathways downstream of ErbB receptors in renal carcinoma and melanoma cells (Figures 3 and 4, Supplementary Figure 3).